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Forecasting the impact of diabetes mellitus 
on tuberculosis disease incidence and 
mortality in India
Background In context of the rapidly expanding diabetes mellitus (DM) 
epidemic in India and slowly declining tuberculosis (TB) incidence, we 
aimed to estimate the past, current, and future impact of DM on TB epi-
demiology.
Methods An age-structured TB-DM dynamical mathematical model was 
developed and analyzed to assess the DM-on-TB impact. The model was 
calibrated using a literature review and meta-analyses. The DM-on-TB im-
pact was analyzed using population attributable fraction metrics. Sensi-
tivity analyses were conducted by accommodating less conservative effect 
sizes for the TB-DM interactions, by factoring the age-dependence of the 
TB-DM association, and by assuming different TB disease incidence rate 
trajectories.
Results In 1990, 11.4% (95% uncertainty interval (UI) = 6.3%-14.4%) 
of new TB disease incident cases were attributed to DM. This proportion 
increased to 21.9% (95% UI = 12.1%-26.4%) in 2017, and 33.3% (95% 
UI = 19.0%-44.1%) in 2050. Similarly, in 1990, 14.5% (95% UI = 9.5%-
18.2%) of TB-related deaths were attributed to DM. This proportion in-
creased to 28.9% (95% UI = 18.9%-34.1%) in 2017, and 42.8% (95% 
UI = 28.7%-53.1%) in 2050. The largest impacts originated from the effects 
of DM on TB disease progression and infectiousness. Sensitivity analyses 
suggested that the impact could be even greater.
Conclusions The burgeoning DM epidemic is predicted to become a lead-
ing driver of TB disease incidence and mortality over the coming decades. 
By 2050, at least one-third of TB incidence and almost half of TB mortal-
ity in India will be attributed to DM. This is likely generalizable to other 
Asian Pacific countries with similar TB-DM burdens. Targeting the impact 
of the increasing DM burden on TB control is critical to achieving the goal 
of TB elimination by 2050.
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Although tuberculosis (TB) remains a public health concern globally, sever-
al countries are disproportionally affected by TB [1]. India harbors the largest 
number of individuals with TB worldwide, with at least twice as many cases as 
any other country [1]. In 2016, 2.8 million incident TB disease cases (27% of 
global TB incidence) and 435 000 TB deaths (26% of global TB deaths) were 
estimated in India [1].
TB disease incidence is affected by key risk factors such as diabetes mellitus 
(DM), HIV, under-nutrition, and smoking [2]. In 2017, 73 million Indians were 
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living with DM at a prevalence of 8.8% (95% confidence interval (CI) = 6.7%-10.9%) [3]. India was pro-
jected to account for the highest number of DM cases globally by 2045 at 134 million cases [3]. With India 
burdened by both TB and DM, their synergetic relationship is a major public health concern. A number 
of TB-DM epidemiological studies have been conducted in this country [4-9], with recent data reporting 
high DM prevalence among TB patients [10].
DM increases the risk of TB infection [11] and disease [12-14], and has adverse impacts on TB treatment 
outcomes (eg, DM increases the risk of mortality during TB treatment, TB relapse, and possibly multi-
drug resistant TB) [15-20]. Several biological mechanisms appear to explain the synergetic TB-DM asso-
ciation [21-33]. For example, the hypothesis that DM impairs the innate and adaptive immune respons-
es, such as interferon-C (IFN-c), necessary to prevent the proliferation of TB, is supported by existing 
studies [13,28,30]. Studies showed that, compared to people with no DM, IFN-c levels were significantly 
reduced in people with DM [30], and that IFN-c levels were negatively associated with glycated hemo-
globin levels [31].
A recent study of TB-DM interactions indicated large potential impact for DM on TB incidence including 
both direct (eg, DM increasing the risk of onset of TB disease) and indirect effects (eg, onward transmis-
sion of TB from people with and without DM) [34]. The study concluded that the impact of DM on TB 
epidemiology could be underestimated, if assessed using more conventional population attributable frac-
tion (PAF) approaches such as Levin’s formula [35], that capture only the direct impact of DM on TB [34].
Against this background, we aimed to estimate the past, current, and future impact of DM on TB epide-
miology in India using a dynamical mathematical model. A strength of this study is that it accounts for 
the different pathways in which DM affects TB natural history and treatment outcomes, and incorporates 
a detailed quantitative assessment of the effect sizes of each of the DM-on-TB effects. The study also fac-
tors the projected rise of the DM epidemic in India over the coming decades, and assesses both the direct 
and indirect population impacts of DM on TB. The TB-DM model was applied to India to demonstrate 
the utility of our approach in a country highly burdened with both diseases, however, can be implement-
ed in additional countries.
METHODS
We constructed an age-structured deterministic compartmental model to characterize the impact of DM 
on TB epidemiology in India by extending a recently developed analytical approach [34]. The model was 
also designed based on a recently developed conceptual framework for TB-DM interactions [34]. The 
model was coded and analyzed in MATLAB R2015a [36].
Mathematical model
The model is described by a system of coupled nonlinear differential equations stratifying the Indian pop-
ulation by age group, TB infection status, TB infection stage, TB disease form, TB treatment status, TB 
recovery status, and DM status. Details of the model can be found in the Online Supplementary Docu-
ments (Appendix S1 and S2 in the Online Supplementary Document).
The population was stratified into 20 5-year age bands representing the age cohort 0-99 years. Upon in-
fection, TB progression was stratified into the two stages: latent-slow TB infection (LSI) and latent-fast TB 
infection (LFI). TB disease was stratified into the three clinically-relevant forms: smear-positive pulmonary 
(SP-PTB), smear-negative pulmonary (SN-PTB), and extra-pulmonary (EP-TB) [37,38]. The proportion 
of individuals developing each infection and disease form was age-dependent, and only the pulmonary 
forms were considered infectious. Treatment was assumed to last for six-months reflecting the directly-ob-
served treatment short-course (DOTS) therapy [39].
Individuals with DM followed a distinct TB natural history from that of non-DM individuals–TB natu-
ral history was modulated by specific effects of having concurrent DM (Figure S1 in the Online Supple-
mentary Document). Based on empirical evidence, DM was assumed to affect TB natural history and 
treatment outcomes through 10 different pathways [34]. The effects, their definitions, their effect sizes, 
and the evidence supporting them are summarized in Table 1 and discussed in Appendix S2.2 in On-
line Supplementary Document.
Briefly, compared to non-DM individuals, DM increased susceptibility to TB infection (Effect 1-Susceptibil-
ity), proportion of TB infections entering LFI vs LSI states (Effect 2-Fast progression), proportion of those 
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developing SP-PTB (vs SN-PTB) for those with 
pulmonary TB disease (Effect 5-Smear positivity), 
and TB infectiousness among those with pulmo-
nary TB disease (Effect 6-Disease infectiousness). 
Furthermore, compared to non-DM individu-
als, DM increased the risk of TB-related mortality 
(Effect 7-TB mortality), reduced the proportion of 
successful treatment among those undergoing TB 
treatment (Effect 8-Treatment failure), delayed the 
resolution of TB disease (Effect 9-Recovery), and 
increased susceptibility to TB reinfection after re-
covery (Effect 10-Cured reinfection).
Amongst those with DM comparative to without, 
susceptibility to develop TB disease among those 
with LSI (Effect 3-Reactivation), and susceptibili-
ty to TB reinfection among those with LSI (Effect 
4-Primary reinfection), were set as having no effect, 
as the impacts of these pathways were captured 
by Effect 2–Fast progression (Appendix S2.2 in the 
Online Supplementary Document). Also, given 
heterogeneity of evidence [20], the proportion of 
successful treatment among those with DM un-
dergoing TB treatment (Effect 8-Treatment failure) 
was set as equal to those without DM undergoing 
TB treatment (Appendix S2.2 in Online Supple-
mentary Document).
Data sources and model fitting
TB natural history model parameters (in absence 
of DM) were based on available empirical evi-
dence [37], or through model fitting to empirical 
data. Table S1 in Online Supplementary Docu-
ment lists the parameter values and their sources.
The key assumptions for the effect sizes of the 10 
DM-on-TB effects were based mostly on pooled 
evidence from systematic reviews and/or me-
ta-analyses, or derived from specific observation-
al studies (Table 1 and Appendix S2.2 in Online 
Supplementary Document). Given heterogene-
ities and uncertainties around the exact effect siz-
es, we opted for a conservative approach whereby 
each effect size was modest, or set at the null value 
if the evidence is conflicting or not firmly estab-
lished (ie, DM has no effect on TB). For example, 
the effect size for Effect 2-Fast progression was set 
as derived using an effect size of only 2.00 for the 
TB-DM association – based on a conservative me-
ta-analysis that pooled studies of different study 
designs (Appendix S2.2 in Online Supplementa-
ry Document) [12]. The effect size for Effect 7-TB 
mortality was based on a recent meta-analysis es-
timating a pooled mean crude odds ratio (OR) 
of 2.11 across 48 studies [20]. Despite evidence 
suggesting that previous TB disease could increase 
the risk of developing DM [49], we opted not to 
account for this bi-directionality given that cur-Ta
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rent evidence is not yet conclusive for this effect. Therefore, our estimates for the impact of the TB-DM 
interactions on TB epidemiology are more likely to underestimate the impact, rather than overestimate it.
The model was fitted using the following India-specific data: TB-incidence and mortality rates as report-
ed in the World Health Organization (WHO) Global Health Observatory data repository [50], national 
and age-specific DM prevalence as reported by the International Diabetes Federation [3,51-55], age-spe-
cific DM prevalence distribution as reported by the nationally-representative Indian Council of Medical 
Research-India Diabetes study [56], and demographics as reported in the database of the Population Di-
vision of the United Nations Department of Economic and Social Affairs [57]. TB contact and case-detec-
tion rates were derived by model fitting to the above data.
TB-DM synergy metric
We estimated the impact of DM on each of TB disease incidence and mortality between 1990 and 2050 
by calculating the “true” PAF [34], ie, the proportion of each of TB incidence and mortality that is direct-
ly (etiologically) and indirectly (such as onward transmission) attributed to DM (Appendix S3 in Online 
Supplementary Document). In contrast with Levin’s PAF [35] which only estimates the direct population 
impact of DM on TB disease, “true” PAF (below noted only as PAF) was estimated for each of TB incidence 
and mortality as the proportional reduction between the measures in a scenario where the synergy in the 
TB-DM relationship is active, compared to a scenario where the synergy is inactive. We assessed the im-
pact of DM on TB epidemiology for each of the DM effects in combinations and individually.
Uncertainty analysis
A multivariate uncertainty analysis was conducted factoring the uncertainty in our knowledge of the DM-
on-TB effect sizes (Table 1). We used Monte Carlo sampling from either the CI for the TB-DM effect sizes, 
or assuming (if uncertainty is not captured by CI) ±25% uncertainty around the point estimates for the 
effect sizes. We implemented 500 uncertainty runs of the model. In each run, the values of the effect sizes 
were randomly selected from their specified ranges, and the model was refitted to India’s country-specific 
data. The mean and 95% uncertainty intervals (UI) for the PAFs were derived from the likelihood distri-
bution generated by the uncertainty runs.
Sensitivity analyses
Given that our main estimates were generated using a conservative approach, we conducted two sensitivity 
analyses with less conservative effect sizes for the TB-DM interactions. In the first sensitivity analysis, we 
used, for Effect 2-Fast progression, the TB-DM association effect size of 3.59 based on the prospective cohort 
studies (Appendix S2.2 in Online Supplementary Document) [12], In the second sensitivity analysis, 
we used, for Effect 7-TB mortality, the effect size of 4.95 based on the pooled analysis that included studies 
that appropriately adjusted for confounders Appendix S2.2 in Online Supplementary Document) [20].
In a third sensitivity analysis, we explored the TB-DM synergy implications by factoring the age-depen-
dence of the TB-DM association, based on a cohort study that estimated the age-specific relative risks 
(RRs) of the effect of DM on TB disease [58]. In doing so, we scaled down (conservatively) the age effects 
reported by Kim et al [58], to reach the assumed 2-fold overall RR (Appendix S2.2 in Online Supple-
mentary Document).
In a fourth sensitivity analysis, in context of uncertainty about the future trajectory of the TB epidemic 
over the coming decades, we assessed the TB-DM synergy implications assuming 10 different TB disease 
incidence rate trajectories over the coming decades. The change in TB incidence rate at 2050, relative to 
the baseline model scenario, was assumed to range between ±50%.
In a fifth sensitivity analysis, we accounted for the age-dependency in the proportion of individuals de-
veloping each infection form (LSI vs LFI) for those aged 15 years and above, compared with the baseline 
analysis in which this proportion did not differ by age for adults. Specifically, as informed by evidence 
[59], we assessed the TB-DM synergy implications assuming that 25% of individuals who progress to TB 
infection aged 15-35 years develop LFI, while only 5% of individuals aged 35+ years develop LFI.
In a sixth sensitivity analysis, we assessed the implications of assuming different TB reinfection risks 
[60,61]. We compared a 65% fractional reduction in the susceptibility to TB reinfection (compared to ini-
tial TB infection risk; our baseline assumption, Table S1 in Online Supplementary Document) [62,63], 
to no reduction, and to a 35% fractional increase. The different risks of reinfection were assumed for 1) 
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individuals with LSI (that is those in latent infection), 2) individuals who successfully completed TB treat-
ment, or 3) both individuals with LSI and those who successfully completed TB treatment.
Finally, additional sensitivity analyses were conducted to assess the sensitivity of model predictions to 
variations in the effect sizes of the DM-on-TB effects (Table 1). For each individual effect, we used the 
lower and upper values from either the CI for the TB-DM effect sizes, or assuming (if uncertainty is not 
captured by CI) ±25% uncertainty around the point estimates.
RESULTS
The model fitted well the demographic (Figure S4 in Online Supplementary Document), TB incidence 
rate (Figure 1, Panel A), TB mortality rate (Figure 1, Panel C), and DM prevalence data for India (Figure 
2, Panel A). From 2017 to 2050, TB disease incidence rate (defined as the ratio of total annual number 
of TB disease cases over total Indian population) was projected to decrease from 215 to 116 per 100 000 
persons per year (Figure 1, Panel A). Meanwhile, the number of annual new (incident) cases was pro-
jected to decrease from 2.8 to 2.0 million (Figure 1, Panel B). Likewise, TB mortality rate (defined as the 
ratio of total annual number of TB-related deaths over total Indian population) was projected to decrease 
from 40.7 to 15.7 per 100 000 persons per year (Figure 1, Panel C). Meanwhile, the number of annual 
TB deaths was projected to decrease from 534 000 to 287 000 (Figure 1, Panel D). DM prevalence in In-
dia was projected to increase from 8.5% in 2017 to 12.1% in 2050 (Figure 2, Panel A).
While DM prevalence increased (Figure 2, Panel A) and TB incidence rate decreased (Figure 1, Panel 
A), the proportion of new TB incidence cases and proportion of TB-related deaths attributed to DM in-
creased steadily (Figure 2, Panel B). In 1990, 11.4% (95% UI = 6.3%-14.4%) of new TB disease incident 
cases were attributed to DM (Figure 2, Panel B). This proportion increased to 21.9% (95% UI = 12.1%-
26.4%) in 2017, and was predicted to continue increasing to 33.3% (95% UI = 19.0%-44.1%) by 2050. 
Similarly, in 1990, 14.5% (95% UI = 9.5%-18.2%) of TB-related deaths were attributed to DM. This pro-
portion increased to 28.9% (95% UI = 18.9%-34.1%) in 2017, and was predicted to continue increasing 
to 42.8% (95% UI = 28.7%-53.1%) by 2050.
Relaxing the conservative approach by using, for Effect 2-Fast progression, the TB-DM association effect 
size of 3.59 [12], resulted in a larger impact for the TB-DM synergy on TB disease incidence and mortali-
ty (Figure 3, Panel A). In 1990, 17.2% of TB disease incident cases were attributed to DM, and this pro-
Figure 1. Model projections. Panel A. Tuberculosis (TB) disease incidence rate. Panel B. Number of annual new 
(incident) TB disease cases. Panel C. TB mortality rate. Panel D. Number of annual TB deaths, in India between 
1990 and 2050. The red asterisks in panels A and C are the data provided by the World Health Organization’s 
Global Health Observatory data repository [50].
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portion increased to 37.0% by 2017 and 55.4% by 2050. 
Meanwhile, in 1990, 19.2% of TB-related deaths were at-
tributed to DM, and this proportion increased to 42.1% 
by 2017 and 60.8% by 2050.
Relaxing the conservative approach by using, for Effect 
7-TB mortality, the effect size of 4.95 [20], resulted in a 
larger impact for the TB-DM synergy on TB mortality but 
slightly smaller impact on TB disease incidence (Figure 
3, Panel B). In 1990, 7.4% of new TB incident cases were 
attributed to DM, and this proportion increased to 16.2% 
by 2017 and 28.2% by 2050. Meanwhile, in 1990, 14.9% 
of TB-related deaths were attributed to DM, and this pro-
portion increased to 31.2% by 2017 and 47.5% by 2050.
Exploring the TB-DM synergy implications by factoring 
the age-dependence of the TB-DM association, resulted in 
a larger impact on TB disease incidence and mortality (Fig-
ure 3, Panel C). In 1990, 13.2% of new TB incident cases 
were attributed to DM, and this proportion increased to 
27.9% by 2017 and 39.2% by 2050. Meanwhile, in 1990, 
15.3% of TB-related deaths were attributed to DM, and 
this proportion increased to 33.3% by 2017 and 45.41% 
by 2050.
Assessing the TB-DM synergy implications at different TB 
disease incidence trajectories over the coming decades re-
sulted in minimal changes in the assessed impact of DM 
on TB incidence and mortality (Figure S5 in Online Sup-
plementary Document). In 2050, new TB incident cas-
es attributed to DM ranged between 26.5% and 34.5%, 
and TB-related deaths attributed to DM ranged between 
37.2% and 43.7%.
Factoring the age-dependency in the proportion of indi-
viduals developing each infection form (LSI vs LFI) for 
those aged 15 years and above, the impact of DM on TB 
disease incidence and mortality was reduced (Figure S6 in 
Online Supplementary Document). In 1990, only 6.2% 
of new TB incident cases were attributed to DM, and this proportion increased to 12.6% by 2017 and 
20.4% by 2050. Meanwhile, in 1990, 8.2% of TB-related deaths were attributed to DM, and this propor-
tion increased to 17.7% by 2017 and 28.6% by 2050.
Exploring the TB-DM synergy implications assuming no change in the susceptibility to TB reinfection, 
resulted in slightly larger impact for DM on TB disease incidence and mortality (Figure S7 in Online 
Supplementary Document). By 2050, assuming no change in the susceptibility to TB reinfection among 
individuals who successfully completed TB treatment, with LSI, and both with LSI and those who success-
fully completed TB treatment, new TB incident cases attributed to DM were 33.8%, 38.6%, and 38.8%, 
respectively, and TB-related deaths attributed to DM were 42.1%, 44.9%, and 45.7%, respectively (Figure 
S7 in Online Supplementary Document). Exploring the TB-DM synergy implications assuming a 35% 
increase in the susceptibility to TB for reinfection, resulted in a relatively larger impact for DM on TB dis-
ease incidence and mortality (Figure S7 in Online Supplementary Document). By 2050, assuming 35% 
increase in the susceptibility to TB reinfection among individuals who successfully completed TB treat-
ment, with LSI, and both with LSI and those who successfully completed TB treatment, new TB incident 
cases attributed to DM were 33.5%, 47.7%, and 48.9%, respectively, and TB-related deaths attributed 
to DM were 42.6%, 54.3%, and 57.1%, respectively (Figure S7 in Online Supplementary Document).
Table 2 and Table 3 show the individual impact of each of the DM-on-TB effects at six different time 
points. Most effects resulted in a larger TB disease incidence and mortality, as DM prevalence increased 
with time. The largest impact for TB incidence was for Effect 2-Fast progression followed by Effect 6-Infec-
tiousness (Table 2). The proportion of TB incidence attributed to Effect 2-Fast progression increased from 
Figure 2. Diabetes mellitus (DM) and its projected impact on tu-
berculosis (TB). Panel A. Model projections for DM prevalence 
in India between 1990 and 2050. Panel B. Model predictions 
for the proportion of TB disease incident (solid black line) and 
mortality (dashed blue line) cases attributed to DM in India be-
tween 1990 and 2050. The blue and red asterisks in Panel A are 
DM prevalence data provided by the International Diabetes Fed-
eration (IDF) [53].
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8.7% in 1990 to 25.1% by 2050. The proportion 
of TB incidence attributed to Effect 6-Disease infec-
tiousness increased from 4.5% in 1990 to 14.8% by 
2050. The largest impact for TB mortality was also 
for Effect 2-Fast progression followed by Effect 6-In-
fectiousness (Table 3). The proportion of TB-relat-
ed deaths attributed to Effect 2-Fast progression in-
creased from 9.9% in 1990 to 28.5% by 2050. The 
proportion of TB-related deaths attributed to Effect 
6-Disease infectiousness increased from 4.3% in 1990 
to 14.4% by 2050.
Effect 7-TB mortality increased TB-related deaths 
from 2.1% in 1990 to 10.3% by 2050, but it re-
duced TB disease incidence with less TB transmis-
sion (due to the premature death of persons with 
TB disease). The impact of Effect 5-Smear positivity 
and Effect 10-Cured reinfection on both TB incidence 
and mortality changed in direction with time—a 
consequence of a complex interplay between TB 
enhanced transmission, premature death of TB dis-
ease cases, and demographic factors relating to DM 
age-specific prevalence distribution and TB expo-
sure risk variation in successive birth cohorts.
DISCUSSION
We provided a comprehensive quantitative assess-
ment of the impact of DM on TB epidemiology in 
India, a country heavily burdened by both diseas-
es. Anchored on a solid foundation of current em-
pirical evidence, the assessment accounted for both 
direct and indirect impacts, and factored the differ-
ent effects by which DM can affect TB natural his-
tory and treatment outcomes. As DM prevalence 
increased and TB disease incidence declined, DM 
was predicted to play a major and growing role in 
TB epidemiology. While in 1990 only one in 10 TB 
disease cases was attributed to DM, currently one in 
five is attributed to DM, and by 2050, one in three 
will be attributed to DM. While in 1990 only one 
in seven TB-related deaths was attributed to DM, 
currently nearly one in three is attributed to DM, 
and by 2050, nearly one in two will be attributed 
to DM. These findings highlight how DM could be emerging as the leading driver of TB incidence and 
mortality in India, and likely elsewhere.
The results support growing evidence highlighting the increasing role of DM on TB epidemiology [2,64,65], 
but also suggest that DM impact could be underestimated. We investigated DM role using a conservative 
approach whereby the effect size for each DM-on-TB effect was set at its lowest or null value. Setting effect 
sizes based on best quality evidence, resulted in even larger impact of DM on TB, particularly so for TB 
mortality – half of TB disease cases and TB-related deaths could be attributed to DM by 2050 (Figure 3).
Although the clinical effects of DM on TB treatment outcomes have been widely discussed and researched 
[20], the population impact has been less investigated but shown in this study to play an influential role 
(such as that of Effect 7-TB mortality). However, most of the impact of DM on TB was driven by the effects 
of DM on TB natural history – in particular Effect 2-Fast progression and Effect 6-Disease infectiousness (Ta-
ble 2 and Table 3). These findings suggest that intervention strategies should target DM patients before 
onset of TB disease. The population-level impacts of different intervention strategies, such as screening, 
Figure 3. Sensitivity analyses. Model predictions for the proportion of tu-
berculosis (TB) disease incident (solid black line) and mortality (dashed 
blue line) cases attributed to DM in India between 1990 and 2050 as-
suming: Panel A. TB-DM association effect size of 3.59 based on pooling 
the data only from the prospective cohort studies (Effect 2-Fast progres-
sion, Appendix S2.2 in Online Supplementary Document [12]. Panel 
B. Effect 7-TB mortality effect size of 4.95 based on the pooled analysis 
that included only studies that appropriately adjusted for confounders 
(Appendix S2.2 in Online Supplementary Document) [15]. Panel C. 
Age-dependence in the TB-DM association based on a cohort study that 
estimated the age-specific relative risks of the effect of DM on TB disease 
(Effect 2-Fast progression, Appendix S2.2 in Online Supplementary Docu-
ment) [58].
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case-finding, and intensified treat-
ment, need to be investigated factor-
ing the different DM-on-TB effects.
Our findings demonstrate that sub-
stantial reductions in TB disease in-
cidence and mortality in India, and 
likely in the countries burdened 
by both TB and DM, are difficult 
to achieve without focusing on the 
high-level determinants and risk 
factors for TB including DM, as 
stressed in the WHO’s post-2015 TB 
strategy [66] and in The Collabora-
tive Framework for Care and Control 
of Tuberculosis and Diabetes launched 
in 2011 by the WHO and Interna-
tional Union Against Tuberculosis 
and Lung Disease (The Union) [16], 
and as reinforced and expanded by 
the joint Union’s and World Diabe-
tes Foundation’s “2014 Call for Ac-
tion” [67] and the TB-DM Bali Dec-
laration in 2015 [68]. Indeed, only 
a country-by-country approach, fol-
lowing the concept of “know your 
epidemic” for managing TB, may ad-
vance TB efforts towards TB elimi-
nation by 2050. While historically 
TB has been a general population in-
fection and disease, its epidemiology 
could be transitioning into a new era 
driven by the dynamics of this infec-
tion in high risk populations such 
people living with DM.
Our study has limitations mostly 
related to incomplete knowledge 
of the TB-DM epidemiology. We in-
cluded different DM-on-TB effects 
based on extensive literature review 
and meta-analyses of existing data 
(Appendix S2.2 in Online Supple-
mentary Document), but we may 
have overlooked effects not yet sup-
ported by evidence. For example, 
Effect 6-Disease infectiousness is an ef-
fect that has not been directly inves-
tigated in the literature, but seems 
to have a major population-level im-
pact on TB epidemiology through its 
effect on the onward transmission 
of the infection. The parametriza-
tion of Effect 6-Disease infectiousness 
was based on biologically-motivat-
ed plausible assumptions that need 
to be investigated in detail through 
further epidemiological/biological 
studies.Ta
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Evidence suggests heterogeneities and uncertainties around the exact effect sizes of several effects. For 
example, not all risk estimates were available by age strata, though age could be an important factor 
in determining the population impact of DM on TB. Moreover, even though evidence supports an in-
creased risk of developing TB disease for those with DM [12], it does not differentiate the precise biolog-
ical mechanism(s) of whether DM is acting through Effect 2-Fast progression, Effect 3-Reactivation, and/or 
Effect 4-Primary reinfection.
Our conclusion is predicated upon the assumption that the effect of DM on TB is causal. While strongly 
plausible, the scale of TB-DM biological/epidemiological synergy is not completely certain. The associa-
tion could be affected by confounders (such as smoking and obesity), which are not controlled for giv-
en the very complex overlap and interactions between TB and DM. For example, the TB-DM interaction 
is paradoxical; while DM is known to be associated with obesity [69], TB is reportedly associated with 
low body mass index (ie, obesity is a protective factor against TB disease) [70]. However, when obesity 
and DM (a serious metabolic disorder) coexist, the protective effect of obesity on TB is attenuated [71].
We did not include all factors that may influence the impact of DM on TB, or the factors that may af-
fect directly each of TB or DM burdens individually [12,17,72,73]. For example, the impact of HIV as 
a co-factor [17,72,73] was not incorporated. However, despite the potential public health implications, 
HIV prevalence is relatively low in India at less than 1.0% [74], hence, probably minimally affecting our 
results and conclusions.
We modeled TB’s natural history and dynamics based on the canonical approach in the literature [37,75], 
but TB’s complex natural history remains insufficiently-understood [59]. For instance, based on studies 
by Heimbeck [62,63], we assumed a proportional reduction in the susceptibility to TB reinfection with 
prior TB exposure (ie, acquired protective immunity), however, this immunity may be explained by se-
lection bias as these studies were conducted among individuals who may not have been representative 
of the wider population [61]. Other evidence suggests a higher risk of reinfection rather than protective 
immunity [60]. Moreover, though we assumed that the proportion of individuals developing LSI vs LFI 
was age dependent, this was assumed for only children vs adults, but the variable age dependence could 
also affect the adult population [59].
We did not factor the effect of intermediate hyperglycemia (pre-DM) on TB, which may enhance the im-
pact of DM on TB [12,76]. We only included the DM-on-TB effects, but the links between the two dis-
eases could be bi-directional [49]. Last but not least, the impact of DM on TB depends on the trajectory 
of the TB epidemic over the coming decades, but this trajectory may change substantially with roll-out 
and scale-up of interventions in upcoming years [1].
Despite these limitations, our study has several strengths. Our model includes ten different effects in which 
DM affects TB natural history and treatment outcomes, incorporates a detailed quantitative assessment of 
the effect sizes for each effect, is age stratified to reflect the age-specific trends, and assesses both the di-
rect and indirect population impacts of DM on TB. In addition, most of the potential limitations are likely 
to lead to underestimation rather than overestimation of the impact of DM on TB.
We also conducted sensitivity analyses to explore the potential impact of several mentioned limitations, 
and these analyses confirmed our results, or suggested that the impact could be underestimated (Figure 
3 and Figures S5 and S7 in the Online Supplementary Document), or slightly overestimated (Figure 
S6 in Online Document). Furthermore, our sensitivity analyses demonstrated that our results are most 
sensitive to Effect 2-Fast progression, Effect 6-Disease infectiousness, and Effect 1-Susceptibility (Figure S9 in 
Online Supplementary Document), as expected given the impact of these effects on TB-epidemiolo-
gy (Table 2 and Table 3). Otherwise, our results were largely insensitive to variations in the rest of ex-
plored effects (Figure S9 in Online Supplementary Document). We further conducted a multivariate 
uncertainty analysis by factoring the uncertainty in model parameters, and the uncertainty intervals of 
the model outcomes affirmed the validity of our predictions (Figure S8 in Online Supplementary Doc-
ument). Finally, the aim of the present analysis was to assess the epidemiological implications of the TB-
DM interactions focusing on the core interaction effects and at the national level. Thus, we resorted to a 
parsimonious model structure presenting “average” impact estimates of DM on TB, rather than stratified 
estimates for specific population strata.
In conclusion, the burgeoning DM epidemic in India is predicted to become a leading driver of TB dis-
ease incidence and mortality over the coming decades in India and possibly elsewhere. At present, one in 
five TB disease cases is attributed to DM, and by 2050, one in three will be attributed to DM. Nearly one 
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in three TB-related deaths is attributed to DM currently, and by 2050, nearly one in two will be attribut-
ed to DM. The slowly declining TB incidence, in context of rapidly expanding DM epidemic in multiple 
countries, could be driving a major turn in TB epidemiology. Targeting the impact of the increasing DM 
burden on TB control is critical to achieving the goal of TB elimination by 2050.
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